This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Druker BJ, Guilhot F, O’Brien SG, Gathmann I, Kantarjian H, Gattermann N et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006; 355: 2408–2417.
Rousselot P, Huguet F, Rea D, Legros L, Cayuela JM, Maarek O et al. Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood 2007; 109: 58–60.
Thiele J, Kvasnicka HM, Schmitt-Graeff A, Kriener S, Engels K, Staib P et al. Bone marrow changes in chronic myelogenous leukaemia after long-term treatment with the tyrosine kinase inhibitor STI571: an immunohistochemical study on 75 patients. Histopathology 2005; 46: 540–550.
Baccarani M, Saglio G, Goldman J, Hochhaus A, Simonsson B, Appelbaum F et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2006; 108: 1809–1820.
Greer JP, Foerster J, Lukens JN, Rodgers GM, Paraskevas F, Glader BE . Examination of blood and bone marrow. Wintrobe's Clinical Hematology,, 11th edn. Lippincott Williams & Wilkins: Philadelphia, 2003, 1–25.
Lundan T, Volin L, Elonen E, Autio K, Knuutila S . Clinical and practical value of metaphase fluorescent in situ hybridization in follow-up after allogeneic stem cell transplantation in chronic myeloid leukemia. Haematologica 2004; 89: 247–249.
Bocchia M, Abruzzese E, Forconi F, Ippoliti M, Trawinska MM, Pirrotta MT et al. Imatinib does not impair specific antitumor T-cell immunity in patients with chronic myeloid leukemia. Leukemia 2006; 20: 142–143.
Mohty M, Jourdan E, Mami NB, Vey N, Damaj G, Blaise D et al. Imatinib and plasmacytoid dendritic cell function in patients with chronic myeloid leukemia. Blood 2004; 103: 4666–4668.
Acknowledgements
Dr S Siitonen is acknowledged for the valuable help with the flow cytometry and the laboratory technicians in the Laboratory of Hematology, HUSLAB are acknowledged for their expert technical assistance. This work was supported by the Finnish special governmental subsidy for health sciences, research and training, The Signe and Ane Gyllenberg foundation, and the Finnish Cancer Organizations.
Author information
Authors and Affiliations
Corresponding author
Additional information
Supplementary Information accompanies the paper on the Leukemia website (http://www.nature.com/leu)
Supplementary information
Rights and permissions
About this article
Cite this article
Mustjoki, S., Lundán, T., Knuutila, S. et al. Appearance of bone marrow lymphocytosis predicts an optimal response to imatinib therapy in patients with chronic myeloid leukemia. Leukemia 21, 2363–2368 (2007). https://doi.org/10.1038/sj.leu.2404807
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2404807
This article is cited by
-
Assessment of bone marrow lymphocytic status during tyrosine kinase inhibitor therapy and its relation to therapy response in chronic myeloid leukaemia
Journal of Cancer Research and Clinical Oncology (2016)
-
Biological therapy and the immune system in patients with chronic myeloid leukemia
International Journal of Hematology (2012)
-
Does chemotherapy modify the immune surveillance of hematological malignancies?
Leukemia (2009)